BeOne Medicines vs Waters

BeOne Medicines (ONC), health care, and Waters (WAT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Waters is worth $88.4B on the stock market and BeOne Medicines $47.2B: Waters is valued at 87% more. BeOne Medicines trades at 53.0 times earnings and Waters at 188; operating margins in their latest fiscal years were 8.37% and 25.4%. Over the past year BeOne Medicines's share price has moved +13.0% and Waters's +20.4%.

Key facts

BeOne Medicines market value
$47.2B
Waters market value
$88.4B
BeOne Medicines P/E
53.0
Waters P/E
188
BeOne Medicines revenue
$5.3BFY to 2025-12-31
Waters revenue
$3.2BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

BeOne Medicines vs Waters: every measure side by side
Measure BeOne Medicines Waters
SectorHealth CareHealth Care
Country Switzerland United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$47.2Blower$88.4Bhigher
Revenue$5.3Bhigher$3.2Blower
Earnings$286.9Mlower$642.6Mhigher
Employees12,000lower15,000higher
Total assets$8.2Bhigher$5.1Blower
Valuation
P/E53.0lower188higher
P/S8.8lower27.9higher
P/B—2.9
Dividend yield—0.00%
Profitability
Operating margin8.37%lower25.4%higher
Balance sheet
Net assets$4.4Bhigher$2.6Blower
Total liabilities$3.8Bhigher$2.5Blower
Total debt$1Blower$1.4Bhigher
Cash on hand$4.5Bhigher$587.8Mlower
Price change
Today+0.48%higher-0.80%lower
1 year+13.0%lower+20.4%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns ONC · Who owns WAT

Further comparisons

Learn

Questions and answers

Which is bigger, BeOne Medicines or Waters?

By market value, Waters is the larger: $88.4B against $47.2B for BeOne Medicines. By revenue in its latest fiscal year, BeOne Medicines is the larger: $5.3B against $3.2B for Waters.

Which has the higher P/E ratio?

Waters: 188, against 53.0 for BeOne Medicines. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Waters: 25.4%, against 8.37% for BeOne Medicines. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Waters: $1.4B, against $1B for BeOne Medicines. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both BeOne Medicines and Waters?

None of the tracked superinvestors holds both in their latest 13F filing. 6 hold BeOne Medicines and 11 hold Waters.

Cite this page

Funkfolio, “BeOne Medicines vs Waters”, data as of 17 November 2026. https://funkfolio.com/compare/onc-vs-wat

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.